Life Sciences Tools and Services
Company Overview of Synexus Limited
Synexus Limited engages in the identification, recruitment, and retention of patients for clinical trials on behalf of sponsors that include pharmaceutical companies, biotech companies, and contract research organizations worldwide. The company offers feasibility assessment, consultancy, project management, and medical imaging services. Its therapeutic areas include cardiovascular, CNS, endocrinology and metabolism, musculoskeletal, respiratory, dermatology, ENT, gastroenterology, infectious diseases, ophthalmology, urology, women’s health, screenable medical conditions, and others. The company was founded in 1998 and is headquartered in Chorley, United Kingdom. It has research centres in th...
Chorley, PR7 1NY
Founded in 1998
Key Executives for Synexus Limited
Chief Executive Officer and Director
Financial Director and Director
Business Development Director
Head of Operations - Germany
Compensation as of Fiscal Year 2015.
Synexus Limited Key Developments
Synexus Seeks Acquisitions
Jun 17 15
Synexus Limited is looking for acquisition. Synexus intends to become a major player in the US, continue to expand its existing network of sites in Europe and Africa and develop a presence in Asia and South America.
Synexus Announces Board Appointments
Jun 9 15
Following the completion of the management buyout of Synexus the new board confirms its intention to expand the company's footprint through organic growth and acquisition. The new board members of Synexus are: Chairman Charles Woler and non-executives Benjamin Harrild, Hywel Evans, Ged Gould and Simon Braham. CEO of Synexus, Christophe Berthoux, and Financial Director of Synexus, Paul Chambers, will remain on the board. Chairman Charles Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies, SMEs and lately in smaller, earlier stage companies - positions included Chairman and CEO of Roche France, Chairman of SmithKline Beecham's European pharmaceutical business, and CEO of Cadus Pharmaceuticals. Benjamin Harrild is the head of UK for the direct lending team of BlueBay Asset Management LLP, and was part of BlueBay's direct lending business from its inception in 2011. Hywel Evans has a wide experience in pharma and the CRO sector. His experience includes being Managing Director of Novo Nordisk UK, Managing Director of Takeda Pharmaceuticals UK, and after joining Quintiles he rose to become President of Europe. He is also Chairman of Western Sussex Hospitals NHS Trust. Ged Gould is Director and Office Head of LDC Manchester - part of the Lloyds Group - and has over 20 years of experience from the advisory arena, private equity, as well as being the Finance Director of two private equity backed businesses. Simon Braham is the Investment Director at LDC Manchester and has over 17 years' experience in advisory, banking, restructuring and private equity.
Synexus Mulls Acquisitions
Jun 9 15
After the completion of the management buyout of Synexus Limited, the new Board intends to expand through organic growth and acquisitions.
Similar Private Companies By Industry
Recent Private Companies Transactions